Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Novartis discontinued development of mavoglurant for fragile X syndrome in April 2014 following disappointing trial results
InChi: InChI=1S/C28H44O6/c1-15(2)16(3)11-24(32)27(6
Splicing inhibition is the mechanistic basis of the anti-tumor activity of isoginkgetin
33)/t11-/m0/s1
α1-adrenoceptor is a G protein-coupled receptor and mediates noradrenaline and adrenaline signal in the central and peripheral nervous systems
Triacsin C 6904 Novartis discontinued development of mavoglurantTriacsin C (WS 1228A), a natural intracellular long chain acyl CoA synthetases (ACSL) inhibitor, is from Streptomyces aureofaciens. Triacsin C inhibits TAG accumulation into lipid droplets (LD) by suppressing ACSL activity. Triacsin C is found to be highly effective against rotavirus replication. Product information CAS Number: 76896 80 5 Molecular Weight: 207. 27 Formula: C11H17N3O Chemical Name: (E) 1 nitroso 2 [(2E,4E,7E) undeca 2,4,7 trien 1